Corient Private Wealth
HAE icon

Corient Private Wealth’s Haemonetics HAE Stock Holding History

Corient Private Wealth’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.85M Buy
64,693
+35,389
+121% +$2.27M 0.01% 920
2026
Q1 		$1.65M Buy
+29,304
New +$1.91M ﹤0.01% 1366
2025
Q4 		– Sell
-5,861
Closed -$286K – 2697
2025
Q3 		$286K Buy
5,861
+628
+12% +$38.9K ﹤0.01% 2151
2025
Q2 		$390K Buy
5,233
+600
+13% +$39.7K ﹤0.01% 1834
2025
Q1 		$294K Sell
4,633
-32
-0.7% -$2.18K ﹤0.01% 1863
2024
Q4 		$364K Buy
4,665
+37
+0.8% +$2.97K ﹤0.01% 1793
2024
Q3 		$372K Sell
4,628
-210
-4% -$17K ﹤0.01% 1907
2024
Q2 		$400K Sell
4,838
-7
-0.1% -$616 ﹤0.01% 1761
2024
Q1 		$414K Buy
4,845
+28
+0.6% +$2.2K ﹤0.01% 1723
2023
Q4 		$412K Buy
4,817
+232
+5% +$20.1K ﹤0.01% 1707
2023
Q3 		$411K Buy
4,585
+14
+0.3% +$1.25K ﹤0.01% 1591
2023
Q2 		$389K Hold
4,571
– – ﹤0.01% 1583
2023
Q1 		$378K Buy
+4,571
New +$370K ﹤0.01% 1494

Other funds holding HAE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Corient Private Wealth's HAE Position: Q2 2026 in Review

Corient Private Wealth increased its Haemonetics (HAE) stake by 121% in Q2 2026, buying an estimated $2.27M and bringing the position to 64,693 shares worth $4.85M. The position accounts for 0.01% of the portfolio, ranked #920.

Corient Private Wealth first reported a position in HAE in Q1 2023 and has held it in 13 quarters since. 329 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

  • Corient Private Wealth held 64,693 shares of Haemonetics worth $4.85M as of Q2 2026.
  • Corient Private Wealth bought 35,389 Haemonetics shares in Q2 2026, an estimated $2.27M.
  • Haemonetics made up 0.01% of Corient Private Wealth's portfolio in Q2 2026, its #920 holding.
  • Corient Private Wealth first reported a position in Haemonetics in Q1 2023 and has held it in 13 quarters since.
  • 329 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.